Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Sera Prognostics, Inc.NASDAQ: SERA

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $3.03M fell 9.1% year over year, ahead of the -10.5% change in trailing-twelve-month research & development. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • Research & development amounted to 16260.5% of revenue in FY2025, down 2869.4 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -9.1% holds above the trailing-twelve-month pace of -10.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.03M-5.8% QoQ
Last fiscal yearDec 2025
$13.17M-10.6% YoY
LTMMar 2026
$12.87M-10.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-9.1%——
1 year-10.6%——
3-year CAGR-2.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
13.17M USD
Year-over-year change
-10.6%
4-year CAGR
+4.6%

Research & Development vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.5% is the 6th highest of 9, against a peer median of -7.5%.
  • Research & development amounts to 22573.7% of revenue for SERA, versus a peer median of 80.5%.
SERA Competitors
Research & Development for SERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGTXCognition Therapeutics, Inc.LTM Mar 2026$32.45M USD-22.6%+7.0%—
SRZNSurrozen, Inc.LTM Mar 2026$32.14M USD+45.7%-7.4%428.8%
HURATuHURA Biosciences, Inc.LTM Mar 2026$21.18M USD+82.5%+30.2%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$19.63M CAD+4.7%+15.5%—
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$13.34M USD-7.2%+1.9%38.8%
SERASera Prognostics, Inc.LTM Mar 2026$12.87M USD-10.5%-2.6%22573.7%
LUCDLucid Diagnostics Inc.LTM Mar 2026$5.46M USD-7.8%+691.2%106.3%
APYXApyx Medical CorporationLTM Mar 2026$3.33M USD-25.7%-9.5%6.0%
STSSSkyAI, Inc.LTM Mar 2026$319.38K USD-20.4%-50.4%80.5%
Peer median (excluding SERA) —-7.5%+4.5%80.5%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue82K268K306K77K81K
Cost of Revenue37K193K210K82K164K
Gross Profit45K75K96K(5K)(83K)
Gross Margin54.9%28.0%31.4%-6.5%-102.5%
Research & Development11.02M14.24M15.23M14.73M13.17M
Selling, General & Admin24.42M31.48M24.69M21.9M23.25M
Operating Expenses35.44M45.73M39.92M36.63M36.42M
Depreciation & Amortization659K756K900K833K940K
EBITDA(33.6M)(43.37M)(35.29M)(32.04M)(30.98M)
EBITDA Margin-40980.5%-16182.5%-11531.7%-41606.5%-38245.7%
Operating Income(35.4M)(45.65M)(39.82M)(36.64M)(36.5M)
Operating Margin-43164.6%-17034.3%-13013.4%-47577.9%-45066.7%
Interest Income145K456K1.64M2.75M4.59M
Interest Expense746K61K55K28K9K
Other Income / Expenses386K1.47M3.58M3.74M4.58M
Income Before Tax(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Pre-Tax Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
Income Tax Expense00000
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Net Margin-42693.9%-16487.3%-11843.8%-42724.7%-39417.3%
EPS (Basic)(1.18)(1.43)(1.16)(0.99)(0.67)
EPS (Diluted)(1.18)(1.43)(1.16)(0.99)(0.67)
Weighted Avg Shares30.77M30.94M31.2M33.16M47.66M
Weighted Avg Shares (Diluted)30.77M30.94M31.2M33.16M47.66M

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.